PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S.
– Jazz to pay an upfront payment of $200 million to PharmaMar
– Opportunity for Jazz to expand its oncology portfolio with lurbinectedin, a late stage asset in relapsed small cell lung cancer (SCLC)
– PharmaMar is also eligible to receive up to $800 million in potential milestone payments in addition to royalties on net…